Articles from Evestia Clinical

LONDON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Evestia Clinical (“the Company” or “the Group”), a leading independent global specialist Contract Research Organization (CRO), today announced the acquisition of ICRC-Weyer GmbH (“ICRC-Weyer”), a Berlin-based, long-established CRO and scientific consultancy. The acquisition strengthens Evestia Clinical's presence in Germany and Europe and further enhances the Company's full-service clinical research solutions for biotech innovators.

LETCHWORTH GARDEN CITY, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Evestia Clinical (“the Company” or “the Group”), a leading independent global specialist Contract Research Organization (CRO), today announced its new Strategic Advisory Board (“SAB”). Sitting separately to the Company’s corporate Board of Directors, the new SAB will provide high-level scientific, operational and geographic guidance across strategic initiatives to support the evolving needs of the biotech innovators the Company partners with.

LONDON and CHARLOTTESVILLE, Va., July 15, 2025 (GLOBE NEWSWIRE) -- Evestia Clinical (“the Company” or “the Group”) has merged with Atlantic Research Group (“ARG”), a US-based CRO, to create a leading independent global specialist CRO group in fast-growing markets. The merger expands Evestia Clinical’s global footprint in the US and broadens its therapeutic and services offering to include neurology and late-stage clinical trial services. The enlarged group also provides access to enhanced technologies to further meet the tailored needs of its clients.